Naloxone Accord (Naloxone Hydrochloride)

Naloxone is an opioid antagonist used in the management of opioid overdose and related toxicity.

• Opioid overdose: provides rapid reversal of respiratory depression, severe sedation, and miosis, restoring adequate ventilation and alertness.
• Opioid‑induced respiratory depression: quickly restores normal breathing patterns and consciousness in patients receiving opioid analgesics or anesthesia.
• Opioid toxicity from prescription or illicit opioids: counteracts life‑threatening effects such as hypotension and bradycardia, allowing stabilization of vital signs.

• Naloxone acts as a competitive antagonist at the μ, κ and δ opioid receptors. By binding to these receptors without activating them, it displaces opioid agonists such as morphine, fentanyl or heroin, thereby reversing their pharmacologic effects. The rapid blockade restores normal neuronal activity in the brainstem respiratory centers, leading to the reversal of opioid‑induced respiratory depression and sedation and other central nervous system depression.

Naloxone may cause a range of adverse reactions, most of which are transient and related to its pharmacologic activity.

Common Side Effects

• Injection site pain or erythema: mild discomfort or redness at the injection site.
• Nausea or vomiting: transient gastrointestinal upset.
• Sweating: increased perspiration often accompanying reversal.
• Tremor or agitation: temporary nervous system activation.
• Dizziness: light‑headed feeling shortly after administration.
• Headache: mild to moderate head pain that resolves quickly.

Serious or Rare Side Effects

• Acute withdrawal syndrome in opioid‑dependent individuals: sudden onset of anxiety, muscle aches, lacrimation and rhinorrhea.
• Severe hypertension or tachycardia: rapid rise in blood pressure or heart rate requiring monitoring.
• Cardiac arrhythmias: irregular heart rhythms that may need medical intervention.

When using Naloxone, several precautions should be observed to ensure safe and effective administration.

• Assess patient condition: confirm opioid overdose before administration.
• Monitor vital signs: observe respiratory rate, oxygen saturation and blood pressure after dosing.
• Prepare for possible withdrawal: opioid‑dependent patients may experience acute withdrawal symptoms.
• Use appropriate dose: follow prescriber’s instructions and titrate based on clinical response.
• Avoid intrathecal use: Naloxone is not indicated for spinal administration.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Naloxone can interact with other medications, influencing their effects or safety profile.

Major Interactions (Avoid)

• Opioid agonists (e.g., morphine, fentanyl): may precipitate severe withdrawal when naloxone is administered.
• Central nervous system depressants (e.g., benzodiazepines): concurrent use may blunt the reversal of respiratory depression.

Moderate Interactions (Monitor Closely)

• Sympathomimetic agents (e.g., epinephrine): may increase risk of hypertension after naloxone.
• Antihypertensive drugs: blood pressure changes may require adjustment.
• Tricyclic antidepressants: potential for additive cardiovascular effects.